FDA To Examine Novartis AG Biosimilar Drug

January 5, 2015 4:31 PM

7 0

The FDA will be examining Novartis’ imitation drug for Amgen’s oncology drug Neupogen this week

Novartis AG’s (ADR) (NYSE:NVS) biosimilar drug, an imitation of Amgen, Inc.’s (NASDAQ:AMGN) blockbuster oncology drug Neupogen, will be examined this week by the US Food and Drug Administration (FDA). This is the first ever attempt to approve cheaper alternatives, as opposed to highly priced biologi...

Read more

To category page